MedTrace Logo

Speech Production Enhancement Using Augmentative Communication for Kids

NCT07173049 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-05-18

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if speech supplementation can improve speech intelligibility in children ages 7 to 17 years with cerebral palsy. The main questions it aims to answer are:

* To what extent can speech supplementation improve intelligibility in children with CP compared with habitual speech produced without speech supplementation?
* How much intelligibility change is necessary for meaningful improvement when children use speech supplementation strategies?

Participants will:

* complete speech and language assessments
* complete a speech pre-test using habitual speech
* learn a speech supplementation strategy with training from a speech-language pathologist
* complete a speech post-test using the speech supplementation strategy
* complete a speech repetition task where specific words are emphasized (emphatic stress)
* use the previously learned speech supplementation strategy + emphasis on specific words while producing a set of sentences

Conditions

  • Cerebral Palsy (CP)
  • Intelligibility, Speech
  • Augmentative and Alternative Communication

Interventions

BEHAVIORAL

AAC Speech supplementation

The speech supplementation intervention involves learning to point to pictures, words, or letters on a communication board while simultaneously producing speech. Children will spend up to 30 minutes learning to use the strategy in one- on-one interaction with a speech therapist and demonstrate mastery by using the strategy successfully on a series of test stimuli.

Sponsors & Collaborators

  • National Institute on Deafness and Other Communication Disorders (NIDCD)

    collaborator NIH

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Katherine C Hustad, PhD · University of Wisconsin, Madison

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
7 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2029-03-31
Completion
2029-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07173049 on ClinicalTrials.gov